Advisory Committee date for review of tisagenlecleucel-T (CTL 019) to treat relapsed refractory B-cell acute lymphoblastic leukemia . - Novartis

The FDA has announced the first advisory committee meeting to review a chimeric antigen receptor (CAR)-T therapy. The Oncologic Drugs Advisory Committee will review Novartis' tisagenlecleucel-T (CTL 019) during a meeting on 12 July 2017. Novartis is seeking approval for the cell therapy for relapsed refractory B-cell acute lymphoblastic leukemia (ALL) in pediatric and young adult patients. It could be the first CAR-T therapy to reach the market.